CA3092143A1 - Compounds with ferroptosis inducing activity and methods of their use - Google Patents
Compounds with ferroptosis inducing activity and methods of their use Download PDFInfo
- Publication number
- CA3092143A1 CA3092143A1 CA3092143A CA3092143A CA3092143A1 CA 3092143 A1 CA3092143 A1 CA 3092143A1 CA 3092143 A CA3092143 A CA 3092143A CA 3092143 A CA3092143 A CA 3092143A CA 3092143 A1 CA3092143 A1 CA 3092143A1
- Authority
- CA
- Canada
- Prior art keywords
- c6alkyl
- c6alkenyl
- independently
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862636614P | 2018-02-28 | 2018-02-28 | |
| US62/636,614 | 2018-02-28 | ||
| PCT/US2019/019854 WO2019168999A1 (en) | 2018-02-28 | 2019-02-27 | Compounds with ferroptosis inducing activity and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3092143A1 true CA3092143A1 (en) | 2019-09-06 |
Family
ID=65729467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3092143A Pending CA3092143A1 (en) | 2018-02-28 | 2019-02-27 | Compounds with ferroptosis inducing activity and methods of their use |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11098040B2 (enExample) |
| EP (1) | EP3759075B1 (enExample) |
| JP (1) | JP7348906B2 (enExample) |
| KR (1) | KR20200135961A (enExample) |
| CN (1) | CN112041301A (enExample) |
| AR (2) | AR114417A1 (enExample) |
| AU (1) | AU2019229256A1 (enExample) |
| BR (1) | BR112020017561A2 (enExample) |
| CA (1) | CA3092143A1 (enExample) |
| EA (1) | EA202091846A1 (enExample) |
| ES (1) | ES3038012T3 (enExample) |
| IL (1) | IL276788A (enExample) |
| MX (2) | MX2020008906A (enExample) |
| SG (1) | SG11202008230PA (enExample) |
| TW (1) | TW202000663A (enExample) |
| WO (1) | WO2019168999A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3013815T3 (en) * | 2019-02-27 | 2025-04-15 | Ferro Therapeutics Inc | Compounds with ferroptosis inducing activity and methods of their use |
| US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
| WO2021041539A2 (en) * | 2019-08-28 | 2021-03-04 | Ferro Therapeutics, Inc. | Compounds and methods of use |
| CN110511253B (zh) * | 2019-09-04 | 2023-10-13 | 上海药明康德新药开发有限公司 | DNA编码化合物库构建中On-DNA四氢-β-咔啉类化合物的合成方法 |
| CN110627786B (zh) * | 2019-10-29 | 2020-11-24 | 株洲千金药业股份有限公司 | 一种他达拉非中间体的制备方法 |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| US11998534B2 (en) * | 2020-02-12 | 2024-06-04 | Eubulus Biotherapeutics Inc. | GPX4 inhibitor in combination with anticancer agent for treating proliferative disease |
| CN115243719B (zh) * | 2020-03-06 | 2024-09-13 | 北京先通生物医药技术有限公司 | CTB006与Ponatinib联合应用 |
| WO2022042657A1 (en) * | 2020-08-26 | 2022-03-03 | Ferro Therapeutics, Inc. | Compounds and methods of use |
| KR20230128471A (ko) * | 2020-12-04 | 2023-09-05 | 에우불루스 바이오테라퓨틱스 인코포레이티드 | 헤테로아릴-아세틸렌, 이의 약제학적 조성물, 및 이의치료적 적용 |
| KR20220139813A (ko) * | 2021-04-08 | 2022-10-17 | 서울대학교산학협력단 | 암 환자의 예후 예측용 바이오마커 및 이의 용도 |
| CN113336748B (zh) * | 2021-04-12 | 2022-03-25 | 北京大学 | 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物 |
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| WO2024015637A1 (en) * | 2022-07-15 | 2024-01-18 | Ferro Therapeutics, Inc. | Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer |
| AU2023324856A1 (en) * | 2022-08-19 | 2025-01-30 | Olema Pharmaceuticals, Inc. | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer |
| US20260199297A1 (en) * | 2022-12-09 | 2026-07-16 | The University Of Toledo | Ferroptosis inducers to treat cancer |
| CN118994147B (zh) * | 2024-07-18 | 2026-01-02 | 中国海洋大学 | 一种基于疏水标签的gpx4蛋白降解剂及其制备方法和应用 |
| CN120923499A (zh) * | 2025-08-08 | 2025-11-11 | 兰州大学 | 一种铁死亡激动剂、缺氧响应型纳米共递送系统及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9514465D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| WO2001094345A2 (en) * | 2000-06-07 | 2001-12-13 | Lilly Icos Llc | Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione |
| CA2411010A1 (en) * | 2000-06-08 | 2001-12-13 | Lilly Icos Llc | Tetracyclic diketopiperazine compounds as pdev inhibitors |
| ES2244659T3 (es) * | 2000-10-02 | 2005-12-16 | Lilly Icos Llc | Derivados de hexahidropirazino (1'2':1,6)-pirido(3,4-b)indol-1,4-diona para el tratamiento de trastornos cardiovasculares y disfuncion erectil. |
| CA2427608C (en) | 2000-11-08 | 2010-05-04 | Lilly Icos Llc | Condensed pyradizindione derivatives as pde inhibitors |
| CA2616366A1 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| EP1914235A1 (en) * | 2006-10-10 | 2008-04-23 | Universite de Lille 2 Droit et Santé | Chiral tetra-hydro beta-carboline derivatives and applications thereof as antiparasitic compounds |
| WO2008103470A2 (en) | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
| FR2916200A1 (fr) * | 2007-05-18 | 2008-11-21 | Fourtillan Snc | Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique |
| WO2011063223A1 (en) * | 2009-11-20 | 2011-05-26 | Southern Research Institute | TETRAHYDRO-β-CARBOLINE DERIVATIVES, SYNTHESIS AND USE THEREOF |
| US9695133B2 (en) * | 2012-07-13 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use |
| WO2015051149A1 (en) | 2013-10-04 | 2015-04-09 | The Trustees Of Columbia University In The City Of New York | Sorafenib analogs and uses thereof |
| EP3094332B1 (en) | 2014-01-15 | 2018-09-12 | The Trustees of Columbia University in the City of New York | Carbonyl erastin analogs and their use |
| US20170342021A1 (en) | 2014-12-16 | 2017-11-30 | Adt Pharmaceuticals, Inc. | Ras-inhibiting indenyl acetamide compounds, compositions, and uses |
| BR112017024328A2 (pt) | 2015-05-29 | 2018-07-24 | Univ Cornell | métodos de tratamento usando nanopartículas ultrapequenas para induzir morte celular de células cancerosas privadas de nutrientes via ferroptose |
| EP3378861B1 (en) | 2015-11-12 | 2021-08-04 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| US20190008961A1 (en) * | 2016-01-07 | 2019-01-10 | The Broad Institute, Inc. | Compounds and methods for increasing tumor infiltration by immune cells |
| WO2017120455A1 (en) | 2016-01-08 | 2017-07-13 | Ecolab Usa Inc. | Heavy oil rheology modifiers for flow improvement during production and transportation operations |
| CN109362222B (zh) | 2016-02-05 | 2021-03-19 | 益方生物科技(上海)股份有限公司 | 选择性雌激素受体降解物及其用途 |
| WO2018118711A1 (en) | 2016-12-19 | 2018-06-28 | The Trustees Of Columbia University In The City Of New York | Small molecule ferroptosis inducers |
| WO2018218087A1 (en) | 2017-05-24 | 2018-11-29 | K-Gen, Inc. | Methods of cancer treatment |
| EP4085919A3 (en) | 2017-07-21 | 2023-02-08 | Novartis AG | Compositions and methods to treat cancer |
| WO2019106434A1 (en) | 2017-12-01 | 2019-06-06 | Collaborative Medicinal Development Pty. Ltd. | Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders |
| WO2019113004A1 (en) | 2017-12-04 | 2019-06-13 | Memorial Sloan Kettering Cancer Center | Methods of cancer treatment via regulated ferroptosis |
| CN109796424A (zh) | 2019-02-19 | 2019-05-24 | 四川大学 | 一种抑制铁死亡的小分子化合物及其制备方法与应用 |
| ES3013815T3 (en) | 2019-02-27 | 2025-04-15 | Ferro Therapeutics Inc | Compounds with ferroptosis inducing activity and methods of their use |
-
2019
- 2019-02-27 US US16/287,805 patent/US11098040B2/en active Active
- 2019-02-27 BR BR112020017561-7A patent/BR112020017561A2/pt not_active IP Right Cessation
- 2019-02-27 WO PCT/US2019/019854 patent/WO2019168999A1/en not_active Ceased
- 2019-02-27 TW TW108106912A patent/TW202000663A/zh unknown
- 2019-02-27 CN CN201980028824.0A patent/CN112041301A/zh active Pending
- 2019-02-27 CA CA3092143A patent/CA3092143A1/en active Pending
- 2019-02-27 KR KR1020207027582A patent/KR20200135961A/ko not_active Withdrawn
- 2019-02-27 ES ES19710558T patent/ES3038012T3/es active Active
- 2019-02-27 SG SG11202008230PA patent/SG11202008230PA/en unknown
- 2019-02-27 EA EA202091846A patent/EA202091846A1/ru unknown
- 2019-02-27 JP JP2020545666A patent/JP7348906B2/ja active Active
- 2019-02-27 MX MX2020008906A patent/MX2020008906A/es unknown
- 2019-02-27 AU AU2019229256A patent/AU2019229256A1/en not_active Abandoned
- 2019-02-27 EP EP19710558.8A patent/EP3759075B1/en active Active
- 2019-02-28 AR ARP190100499A patent/AR114417A1/es not_active Application Discontinuation
-
2020
- 2020-02-27 AR ARP200100540A patent/AR118205A1/es not_active Application Discontinuation
- 2020-08-18 IL IL276788A patent/IL276788A/en unknown
- 2020-08-26 MX MX2023001527A patent/MX2023001527A/es unknown
-
2021
- 2021-07-06 US US17/368,708 patent/US20230039846A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20230039846A1 (en) | 2023-02-09 |
| BR112020017561A2 (pt) | 2020-12-22 |
| EA202091846A1 (ru) | 2021-06-01 |
| JP2021515010A (ja) | 2021-06-17 |
| AR118205A1 (es) | 2021-09-22 |
| ES3038012T3 (en) | 2025-10-08 |
| SG11202008230PA (en) | 2020-09-29 |
| US11098040B2 (en) | 2021-08-24 |
| MX2020008906A (es) | 2021-02-26 |
| EP3759075B1 (en) | 2025-07-23 |
| WO2019168999A1 (en) | 2019-09-06 |
| US20190263802A1 (en) | 2019-08-29 |
| KR20200135961A (ko) | 2020-12-04 |
| AR114417A1 (es) | 2020-09-02 |
| AU2019229256A1 (en) | 2020-09-17 |
| MX2023001527A (es) | 2023-03-06 |
| EP3759075A1 (en) | 2021-01-06 |
| JP7348906B2 (ja) | 2023-09-21 |
| CN112041301A (zh) | 2020-12-04 |
| IL276788A (en) | 2020-10-29 |
| TW202000663A (zh) | 2020-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3759075B1 (en) | Compounds with ferroptosis inducing activity and methods of their use | |
| JP7617890B2 (ja) | タンパク質チロシンホスファターゼ阻害物質及びその使用方法 | |
| EP3931183B1 (en) | Compounds with ferroptosis inducing activity and methods of their use | |
| CN110944990B (zh) | Tlr7/8拮抗剂及其用途 | |
| JP2023516073A (ja) | Ｂｒｄ９の標的分解のための化合物 | |
| US11040964B2 (en) | Compounds and methods of use | |
| US12622905B2 (en) | Aryl pladienolides for the treatment of neoplastic disorders | |
| CA2841095A1 (en) | Spiro compounds as hepatitis c virus inhibitors | |
| CN110461853A (zh) | 苯并噻吩雌激素受体调节剂 | |
| JP2022516685A (ja) | ホスファターゼ結合化合物およびそれらを使用する方法 | |
| TW202227399A (zh) | 化合物及使用方法 | |
| AU2019239952A1 (en) | Compounds and methods for IDO and TDO modulation, and indications therefor | |
| WO2021041536A1 (en) | Benzimidazole and hydrogenated carbazole derivatives as gpx4 inhibitors | |
| RU2815064C2 (ru) | Производные пладиенолида в качестве средств, оказывающих целенаправленное воздействие на сплайсосому, для лечения рака | |
| HK40067758A (en) | Compounds with ferroptosis inducing activity and methods of their use | |
| HK40080107B (en) | Isoindolinone and indazole compounds for the degradation of egfr | |
| HK40080107A (en) | Isoindolinone and indazole compounds for the degradation of egfr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220930 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240731 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250326 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250328 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250328 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250527 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250926 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251127 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260216 |